Mainz Biomed (NASDAQ:MYNZ – Free Report)’s stock is going to reverse split on Tuesday, December 3rd. The 1-40 reverse split was announced on Friday, November 29th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, December 2nd.
Mainz Biomed Stock Performance
MYNZ stock traded down $0.04 during trading on Friday, reaching $0.22. The stock had a trading volume of 7,094,717 shares, compared to its average volume of 1,350,238. The firm has a fifty day moving average price of $0.26 and a 200 day moving average price of $0.39. Mainz Biomed has a 1-year low of $0.19 and a 1-year high of $1.79.
Analyst Ratings Changes
Separately, HC Wainwright downgraded Mainz Biomed from a “buy” rating to a “neutral” rating in a report on Monday.
Mainz Biomed Company Profile
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Read More
- Five stocks we like better than Mainz Biomed
- Low PE Growth Stocks: Unlocking Investment Opportunities
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- The 3 Best Blue-Chip Stocks to Buy Now
- 3 Penny Stocks Ready to Break Out in 2025
- What Are Growth Stocks and Investing in Them
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
